Bio-Techne Corp Stock Price, News & Analysis

Bio-Techne Corporation (NASDAQ:TECH) has launched Abby, an advanced chemiluminescence system designed to automate the traditional Western blotting process. Abby features picogram-level sensitivity and the innovative RePlex™ technology, enabling sequential immunoassays. Additionally, the new Compass software enhances data analysis efficiency. The company also announced the upcoming Stellar™ NIR and IR modules for Jess™, which aim to elevate fluorescence Western blotting sensitivity. Bio-Techne emphasizes that these products contribute to faster, more reproducible results, essential for modern research environments.

Bio-Techne Corporation (NASDAQ: TECH) announced the completion of its acquisition of Asuragen, Inc., valued at $215 million in cash with up to $105 million contingent on future milestones. This acquisition enhances Bio-Techne's portfolio with advanced molecular diagnostic products, including genetic screening and oncology testing kits. It also provides a GMP-compliant manufacturing facility and a CLIA-certified laboratory. The company anticipates significant growth synergies from this deal, particularly in commercializing molecular products for broader market adoption.

Bio-Techne Corporation (NASDAQ: TECH) will host a conference call and webcast on May 6, 2021, at 8:00 a.m. CDT to discuss its third quarter 2021 financial results. Interested participants can join by dialing 1-877-407-9208 or accessing the webcast at public.viavid.com. A recorded replay will be available from 11:00 a.m. CDT on May 6 until 11:00 p.m. CDT on June 6, 2021. In fiscal 2020, Bio-Techne generated approximately $739 million in net sales.

Bio-Techne Corporation (NASDAQ: TECH) announces the launch of Cultrex™ UltiMatrix™ Reduced Growth Factor Basement Membrane Extract (RGF BME), an innovative extracellular matrix hydrogel aimed at enhancing organoid and pluripotent stem cell cultures. This product features increased total protein content, optimized protein composition, and improved tensile strength, while also reducing reliance on growth factors. Dave Eansor, President of Protein Sciences Segment, emphasizes its importance for drug discovery and regenerative medicine, addressing a critical market need.

Bio-Techne Corporation (NASDAQ: TECH) announced it has won the CiteAb COVID-19 Innovation Award for its R&D Systems and Novus brands. This award recognizes Bio-Techne's impactful response to the COVID-19 pandemic through the development of antibodies and scientific tools for research and testing. Bio-Techne has contributed various resources aiding the understanding of COVID-19, including serology assays with EUA approval. This is the fifth consecutive year the company has received a CiteAb award for its antibody innovations.

Bio-Techne Corporation (NASDAQ:TECH) has received CE-IVD certification for its ExoDx™ Prostate test (EPI), allowing it to be performed in Europe. The test, which aids in determining the need for prostate biopsies, has demonstrated a high sensitivity of 92% and a negative predictive value of 89%. With this certification, the EPI-CE test will be available in Bio-Techne’s Munich laboratory, potentially saving over €1,000 per patient by avoiding unnecessary biopsy procedures. This advancement is expected to enhance decision-making for clinicians and patients across Europe.

Bio-Techne Corporation (NASDAQ: TECH) announced preliminary data on its kidney transplant rejection test, ExoTRU™, developed with the Azzi laboratory at Harvard Medical School. This innovative, non-invasive urine-based multigene assay can distinguish between types of kidney rejection, aiding clinical decision-making and patient care. Scheduled for launch in 2021, ExoTRU demonstrates a negative predictive value (NPV) of 93.3% and a positive predictive value (PPV) of 86.2%. The test's introduction is expected to enhance monitoring and management for kidney transplant patients who face challenges with conventional methods.